These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3629 related items for PubMed ID: 31054549

  • 1. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL, Meng WJ, Shu P, Deng XB, Wu B, Jiang D, Zhuang H, Shen YL, Zhou ZG, Wang ZQ, Wang X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr 25; 22(4):349-356. PubMed ID: 31054549
    [Abstract] [Full Text] [Related]

  • 2. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y, Huang SH, Chi P, Wang XJ, Lin HM, Lu XR, Ye DX, Lin Y, Deng Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):281-288. PubMed ID: 32192308
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW, Zhang KN, Wang C, Han JG, Ma HC, Wei GH, Yang Y, Wang ZJ.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):274-280. PubMed ID: 32192307
    [Abstract] [Full Text] [Related]

  • 4. Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial.
    Wang X, Yu Y, Meng W, Jiang D, Deng X, Wu B, Zhuang H, Wang C, Shen Y, Yang L, Zhu H, Cheng K, Zhao Y, Li Z, Qiu M, Gou H, Bi F, Xu F, Zhong R, Bai S, Wang Z, Zhou Z.
    Radiother Oncol; 2018 Nov 25; 129(2):300-305. PubMed ID: 30381141
    [Abstract] [Full Text] [Related]

  • 5. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ, Zhang L, Dong QS, Cai Y, Zhang YZ, Wang L, Yao YF, Zhang XY, Li ZW, Li YH, Sun YS, Wang WH, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov 25; 24(11):998-1007. PubMed ID: 34823301
    [Abstract] [Full Text] [Related]

  • 6. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ, Shen LJ, Wan JF, Zhang H, Wang Y, Wu X, Wang JW, Wang RJ, Sun YQ, Tong T, Huang D, Wang L, Sheng WQ, Zhang X, Cai GX, Xu Y, Cai SJ, Zhang Z, Xia F.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May 25; 26(5):448-458. PubMed ID: 37217353
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH, Zhou CJ, Zhang S, Wang QX, Xiao WW, Ding PR, Chen G, Pan ZZ, Zeng ZF, Gao YH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar 25; 23(3):266-273. PubMed ID: 32192306
    [Abstract] [Full Text] [Related]

  • 9. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
    Chen CJ, Yang CK, Jian JL, Guan S, Xie MM.
    Zhonghua Yi Xue Za Zhi; 2023 Jan 31; 103(4):271-277. PubMed ID: 36660788
    [Abstract] [Full Text] [Related]

  • 10. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer.
    Alvarez JA, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George TJ, Hong T, Yothers G, Philip P, Nelson G, Al Baghdadi T, Alese OB, Zambare W, Omer D, Verheij FS, Bercz A, Kim MJ, Buckley J, Williams H, George M, Garcia R, Gallagher P, O'Reilly EM, Meyerhardt JA, Crawley J, Shergill A, Horvat N, Romesser PB, Hall W, Smith JJ.
    BMC Cancer; 2024 Jul 26; 24(1):901. PubMed ID: 39060961
    [Abstract] [Full Text] [Related]

  • 11. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S, Wang X, Zhuang Y, Bai S, Wu X, Ye Y, Luo H, Yu H, Wang Q, Chang H, Zeng Z, Cai P, Pan Z, Gao Y, Chen G, Xiao W.
    Cancer Med; 2023 Jun 26; 12(12):13352-13360. PubMed ID: 37156624
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X, Wang QX, Xiao WW, Chang H, Zeng ZF, Lu ZH, Wu XJ, Chen G, Pan ZZ, Wan DS, Ding PR, Gao YH.
    Cancer Commun (Lond); 2018 May 21; 38(1):24. PubMed ID: 29784042
    [Abstract] [Full Text] [Related]

  • 13. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W, Wang W, Huang S, Zhou L, Wang G, Chen W.
    Cancer Invest; 2024 Aug 21; 42(7):661-670. PubMed ID: 39037150
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
    Eisterer W, Piringer G, DE Vries A, Öfner D, Greil R, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group.
    Anticancer Res; 2017 May 21; 37(5):2683-2691. PubMed ID: 28476845
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Jia AY, Narang A, Safar B, Zaheer A, Murphy A, Azad NS, Gearhart S, Fang S, Efron J, Warczynski T, Hacker-Prietz A, Meyer J.
    Radiat Oncol; 2019 Aug 19; 14(1):147. PubMed ID: 31426827
    [Abstract] [Full Text] [Related]

  • 17. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    Cercek A, Roxburgh CSD, Strombom P, Smith JJ, Temple LKF, Nash GM, Guillem JG, Paty PB, Yaeger R, Stadler ZK, Seier K, Gonen M, Segal NH, Reidy DL, Varghese A, Shia J, Vakiani E, Wu AJ, Crane CH, Gollub MJ, Garcia-Aguilar J, Saltz LB, Weiser MR.
    JAMA Oncol; 2018 Jun 14; 4(6):e180071. PubMed ID: 29566109
    [Abstract] [Full Text] [Related]

  • 18. Total neoadjuvant treatment of locally advanced rectal cancer with high risk factors in Slovenia.
    Tuta M, Boc N, Brecelj E, Omejc M, Anderluh F, Ermenc AS, Peressutti AJ, Oblak I, Krebs B, Velenik V.
    Radiol Oncol; 2019 Oct 25; 53(4):465-472. PubMed ID: 31652124
    [Abstract] [Full Text] [Related]

  • 19. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T, Wen L, Zhang J, Wu Y, Jiang Y, Chen G, Wang X, Huang S, Wan Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan 25; 22(1):59-65. PubMed ID: 30703795
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W, Zhou H, Jiang J, Zhu Y, Zou S, Jiang L, Tang Y, Liang J, Sun Y, Jiang Z, Qu W, Li Y, Zhou A.
    BMC Cancer; 2023 Jun 27; 23(1):592. PubMed ID: 37370032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 182.